Glucose monitoring
Real-time continuous glucose monitoring (CGM) is advanced glucose monitoring technology that continuously measures interstitial glucose levels, displays the current blood glucose level as well as the direction and rate of change, and uses alarms and alerts to inform patients when blood glucose is exceeding or falling below specified thresholds.
Continuous glucose monitoring (CGM) was first reviewed by the HTA program in 2011.
In 2017, the HCA director selected glucose monitoring for rereview based on newly available published evidence that could change the original coverage determination.
Status: Review in progress
Why is CGM being reviewed?
CGM was proposed for rereview based on new evidence and expanded indications for use.
Primary criteria ranking
- Safety = Medium
- Efficacy = High
- Cost = High
Documentation
| Type | Materials |
|---|---|
| Assessment (2025) | |
| Assessment (2018) | |
| Assessment (2011) |
Assessment timeline (2025)
- Draft key questions published: September 3, 2024
- Public comment period: September 3 to 16, 2024
- Final key questions: October 2, 2024
- Draft report published: January 17, 2025
- Public comment period: January 17 to February 15, 2025
- Final report published: February 25, 2025
- HTCC public meeting: March 21, 2025
- Draft findings and decision published: March 31, 2025
- Public comment period: March 31 to April 14, 2025
- Final findings and decision published: May 22, 2025
All future dates are estimates and subject to change.